Enterprise Value

1.78B

Cash

302.8M

Avg Qtr Burn

-9.24M

Short % of Float

22.05%

Insider Ownership

2.23%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
LIVMARLI (Maralixibat) Details
Chronic pruritus, Alagille syndrome

Approved

Quarterly sales

LIVMARLI (Maralixibat) Details
Liver disease, Progressive familial intrahepatic cholestasis

Approved

Quarterly sales

Chenodal® (chenodiol) Details
Cerebrotendinous xanthomatosis

NDA

Acceptance for review

LIVMARLI (Maralixibat) Details
Bile duct disease, Rare diseases

Phase 2b

Update

Volixibat (VANTAGE) Details
Primary biliary cholangitis, Liver disease

Phase 2b

Update

Volixibat (VISTAS) Details
Liver disease, Primary sclerosing cholangitis

Phase 2b

Update

Volixibat (OHANA) Details
Liver disease, Intrahepatic Cholestasis of Pregnancy

Failed

Discontinued